Revolution Medicines, Inc. Financials

Market Capitalization $7.05 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	-10.58
Forward PE	-9.35
Price to Sales TTM	$
Price to Book MRQ	$3.39
Enterprise to Revenue
Enterprise to EBITDA	-6.24

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-23.09%
Return on Equity TTM	-36.68%

Income Statement

Revenue TTM	$0
Revenue per Share TTM	$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	$-679,953,024
EBITDA	$-782,745,024
Net Income to Common TTM	$-697,505,984
Diluted EPS TTM	$-4.01
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$2,102,674,944
Total Cash per Share MRQ	$11.29
Total Debt MRQ	$
Total Debt to Equity MRQ	6.46
Current Ratio MRQ	13.46
Book Value per Share MRQ	$11.16

Cash Flow

Operating Cash Flow TTM	$-591,310,976
Levered Free Cash Flow TTM	$-349,126,624

RVMD Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	185,896,625
Float Shares	168,192,142
Avg 10 Volume	4,835,710
Avg 30 Volume	None
Shares Short	18,157,402
Short Ratio	11.31
Short % of Shares	10.37%
% Held by Insiders	1.99%
% Held by Institutions	105.97%

Stock Price Summary

Beta	1.10
Fifty Two Week Low	$29.17
Fifty Two Week High	$62.40
Fifty Two Week Change	0.90%
Day 50 MA	$39.50
Day 200 MA	$43.24

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date